BCL2 and cancer: Moreover, we observed an upregulation of other STAT3 target genes, including BCL-XL and BCL2, following olaparib treatment that was abrogated upon STAT3 silencing, supporting the concept that cancer cells via STAT3 hijack the upregulation of survival effectors, as BCL-XL and BCL2 (Supplementary Fig. S3J).